Panacea Biotec share price
NSE: PANACEABIOBSE: 531349Pharmaceuticals & BiotechnologySmall Cap
Panacea Biotec Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on BSE, Apr 1996 on NSE
Last close ₹325.90down ₹3.15 (0.96%)BSE ₹326.15
Share price at the NSE close on 29 Oct 2026. Previous close ₹329.05.
29 Oct: open ₹329.00, high ₹331.70, low ₹323.05
52-week range of traded prices to 29 Oct 2026
₹292.40Low, 30 Mar 2026₹647.00High, 9 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,996 Cr1,088th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −2.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 25,41247.9% delivered
Results
Consolidated; ₹ crore.Panacea Biotec quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +10.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −162.0%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹200 Crup 19.68%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹2.20 CrQuarter to Mar 2026: −₹1.00 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 1.1%
Revenue by quarter
Peak revenue ₹200 Cr, quarter to Jun 2026; lowest ₹133 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Jun 2026, ₹2.20 CrA loss in 3 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 147 | 163 | 133 | 167 | 141 | 165 | 167 | 200 |
| Net profit | 5 | 4 | −2 | 4 | −14 | 4 | −1 | 2 |
| Net margin | 3.2% | 2.7% | −1.5% | 2.4% | −9.9% | 2.4% | −0.6% | 1.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹640 Crup 14.43%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹7.16 CrYear to Mar 2025: −₹8.72 Cr
- Net margin
- −1.1%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 8 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2021, part of the business was demerged on 21 Sep 2020, and figures before the change include the part that left.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 545 | 596 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 640 |
| Net profit | −64 | −76 | 38 | −194 | −148 | 1,078 | −34 | −2 | −9 | −7 |
| Net margin | −11.8% | −12.7% | 8.2% | −35.7% | −23.6% | 163.0% | −7.3% | −0.3% | −1.6% | −1.1% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- VaccinesVaccines, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹410 Crup 32.41%64.1%
- FormulationsFormulations, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹230 Crdown 7.92%35.9%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.Panacea Biotec PE ratio and valuation
Price to book
At or below today's level on 56% of 1,088 trading days over the last 5 years.
LowestHighest
Its median1.45Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −32.9% | – | – | 0.0% |
| 3 years | +39.8% | – | – | 0.0% |
| 5 years | +10.6% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 2 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 461 | 0.04% | ₹0.02 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 217 | 0.04% | ₹79,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Panacea Biotec insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Employees0 purchases, 1 saleNo purchase₹0.12 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹0.12 Cr
- Promoters and promoter group: no market trade · 2 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Panacea Biotec competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Panacea Biotec in market cap.Healthcare companies
Panacea Biotec is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Dishman Carbogen AmcisDCAL | 2,343 | 144.97 | 0.35 | +0.2% | −84.5% | 0.3% | 1.4% | 0.00% |
 Sai ParenteralsSAIPARENT | 2,234 | – | 4.55 | – | – | – | – | 0.00% |
 Sakar HealthcareSAKAR | 2,106 | 49.13 | 6.09 | +48.0% | +119.8% | 13.2% | 16.6% | 0.00% |
 Beta DrugsBETA | 2,057 | 38.05 | 4.70 | – | – | 16.4% | 14.2% | 0.00% |
 Hester BiosciencesHESTERBIO | 1,963 | 14.42 | 5.45 | +4.1% | +262.2% | 40.4% | 11.7% | 0.48% |
 Indoco RemediesINDOCO | 1,934 | 60.54 | 1.89 | +10.8% | – | 3.2% | 1.8% | 0.10% |
 Syncom Formulations (India)SYNCOMF | 1,919 | 22.43 | 4.62 | +0.4% | +48.6% | 22.6% | 19.5% | 0.49% |
 Windlas BiotechWINDLAS | 1,906 | 28.69 | 3.28 | +18.5% | +2.4% | 12.2% | 12.2% | 0.68% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Panacea Biotec dividend history
| Ex-date | Type | Per share |
|---|---|---|
| 19 Sep 2011 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.75 |
| 16 Sep 2010 | Final | ₹0.25 |
| 19 Sep 2008 | Final | 100% of face value (₹1.00 a share) |
| 21 Sep 2007 | Final | 100% of face value (₹1.00 a share) |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Panacea Biotec announcements
Oct 2026
7 Oct · Updates
Sep 2026
29 Sep · Meeting
15 Sep
Panacea Biotec share price by year
Each calendar year to 2025.Panacea Biotec share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 376.30 | −10.1% | 566.20 | 297.25 |
| 2024 | 418.60 | +149.3% | 484.90 | 119.05 |
| 2023 | 167.90 | +18.2% | 177.65 | 107.55 |
| 2022 | 142.05 | −28.5% | 264.95 | 125.75 |
| 2021 | 198.65 | −17.1% | 439.25 | 172.20 |
| 2020Demerger | 239.55 | +82.4% | 245.45 | 97.15 |
| 2019 | 131.30 | −18.0% | 206.65 | 111.10 |
| 2018 | 160.15 | −34.1% | 350.90 | 144.65 |
| 2017 | 243.00 | +106.8% | 288.35 | 118.70 |
| 2016 | 117.50 | −12.4% | 141.05 | 85.35 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. With the demerger of 21 Sep 2020 reinvested, the change in 2020 is +98.9%.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 319.05 | 333.55 | 317.50 | 329.05 | 327.13 | 56,922 | 37.5% |
| 27 Oct 2026 | 310.05 | 324.50 | 307.40 | 319.25 | 321.16 | 95,583 | 64.7% |
| 26 Oct 2026 | 306.65 | 314.05 | 304.80 | 306.75 | 308.83 | 48,069 | 55.8% |
| 23 Oct 2026 | 328.05 | 328.05 | 304.80 | 311.45 | 312.66 | 82,885 | 47.4% |
| 22 Oct 2026 | 335.00 | 338.35 | 326.00 | 326.80 | 331.07 | 40,228 | 55.5% |
| 21 Oct 2026 | 349.00 | 350.35 | 336.10 | 339.50 | 341.79 | 61,807 | 50.4% |
| 19 Oct 2026 | 357.70 | 357.70 | 342.95 | 349.05 | 349.59 | 69,574 | 57.7% |
| 16 Oct 2026 | 356.60 | 363.45 | 351.00 | 359.70 | 358.78 | 25,780 | 52.5% |
| 15 Oct 2026 | 362.85 | 363.00 | 354.00 | 357.00 | 357.34 | 32,719 | 57.8% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Buyback and demerger history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 21 Sep 2020 | Demerger | 0.9174 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
| 31 Oct 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- PANACEABIO
- BSE code
- 531349
- ISIN
- INE922B01023
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.panaceabiotec.com
- CIN
- L33117PB1984PLC022350
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1984
- Registered office
- Ambala - Chandigarh Highwa, Lalru 140501, Punjab
- Share registrar
- Skyline Financial Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments